The reproductive health in Argentina adds a new novelty: in the last hours they launched a modern oral contraceptive combined with a unique active ingredient. The medicine is already marketed in Europe, with a high rate of acceptability and satisfaction among its consumers.
The new alternative targets the female audience and consists of the incorporation of Estretol – a type of estrogen – which represents a milestone for the national pharmaceutical industry. This active ingredient stands out for its high capacity to provide a effective control of the menstrual cycle.
How the new contraceptive works
In detail, the new alternative that is ingested orally uses Estretol as one of its main components. In addition to being effective in menstrual control, this estrogen has a series of additional benefits that help reduce risk of serious adverse effects.
By acting on different parts of the body, the medicine reduces the likelihood of developing hormonal complications common. Thus, it reduces the cardiovascular risk and of thrombosisamong others.
Recent studies showed that it has a better safety profile on breast tissueand that prevents bone demineralization. Additionally, more than 97% of the women who incorporated this new estrogen did not report a decrease in their libido, with a favorable impact on sexual well-being.
The benefits go beyond female reproductive and general health. This innovative contraceptive treatment does not affect the aquatic ecosystemmaking it a combined oral alternative with less environmental impact.
The launch was announced in the last few hours, which represents a milestone in the national pharmaceutical industry. This type of contraceptive is already marketed in Europe with high acceptance and satisfaction among its consumers.
A milestone in the Argentine pharmaceutical industry
In our country, the product is developed entirely in the state-of-the-art hormonal plant located in the industrial-scientific complex of Pilar, Buenos Aires. There, the pharmaceutical company Gador obtained certification from the European Medicines Agency (EMA), international validation that recognizes the excellence in manufacturing practices, investigation and developmentwhich are added to many other certifications from the main national, regional and international control organizations.
Regarding the recent launch, Dr. Mabel Martino (MP 8.478) said: “The arrival of a new pill with Estetrol is excellent news for Argentine women, since introduces a unique, natural estrogen that is only produced during pregnancynow available in contraception. “This advancement offers a safer option, with fewer effects on metabolism and cardiovascular health.”
Martino, who is president of the Federation of Societies of Gynecology and Obstetrics (FASGO), added: “When combined with drospirenone, a modern progestin, it provides efficacy, well-being, and less impact on the body, ideal for those looking to take care of their health without giving up safety“.
For its part, Alfredo Webergeneral director of the laboratory, stated: “This launch highlights our effort and commitment to evolve, innovate and have all the therapeutic options in the oral contraceptive segment, always with the quality that distinguishes us. We are the first to launch this combination with a new estrogen in 70 years, and this achievement fills us with great satisfaction and pride“.
Source: Ambito
I am a 24-year-old writer and journalist who has been working in the news industry for the past two years. I write primarily about market news, so if you’re looking for insights into what’s going on in the stock market or economic indicators, you’ve come to the right place. I also dabble in writing articles on lifestyle trends and pop culture news.
